دورية أكاديمية
Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro .
| العنوان: | Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro . |
|---|---|
| المؤلفون: | Segatto NV; Technology Development Center, Laboratory of Cancer Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil., Simões LD; Technology Development Center, Laboratory of Cancer Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil., Bender CB; Technology Development Center, Laboratory of Cancer Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil., Sousa FS; Technology Development Center, Laboratory of Cancer Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil., Oliveira TL; Technology Development Center, Laboratory of Cancer Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil., Paschoal JDF; Technology Development Center, Laboratory of Cancer Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil., Pacheco BS; Technology Development Center, Laboratory of Cancer Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil., Lopes I; Technology Development Center, Laboratory of Cancer Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil., Seixas FK; Technology Development Center, Laboratory of Cancer Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil., Qazi A; Department of Animal Sciences, University of Illinois, Urbana, IL, United States., Thomas FM; Department of Animal Sciences, University of Illinois, Urbana, IL, United States., Chaki S; Department of Animal Sciences, University of Illinois, Urbana, IL, United States., Robertson N; Albion College, Albion, MI, United States., Newsom J; Albion College, Albion, MI, United States., Patel S; Department of Animal Sciences, University of Illinois, Urbana, IL, United States., Rund LA; Department of Animal Sciences, University of Illinois, Urbana, IL, United States., Jordan LR; Department of Animal Sciences, University of Illinois, Urbana, IL, United States.; Sus Clinicals Inc., Chicago, IL, United States., Bolt C; Department of Animal Sciences, University of Illinois, Urbana, IL, United States.; Sus Clinicals Inc., Chicago, IL, United States., Schachtschneider KM; Sus Clinicals Inc., Chicago, IL, United States., Schook LB; Department of Animal Sciences, University of Illinois, Urbana, IL, United States.; Sus Clinicals Inc., Chicago, IL, United States., Collares TV; Technology Development Center, Laboratory of Cancer Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil. |
| المصدر: | Frontiers in oncology [Front Oncol] 2024 Feb 26; Vol. 14, pp. 1323422. Date of Electronic Publication: 2024 Feb 26 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Introduction: Bladder cancer is a common neoplasia of the urinary tract that holds the highest cost of lifelong treatment per patient, highlighting the need for a continuous search for new therapies for the disease. Current bladder cancer models are either imperfect in their ability to translate results to clinical practice (mouse models), or rare and not inducible (canine models). Swine models are an attractive alternative to model the disease due to their similarities with humans on several levels. The Oncopig Cancer Model has been shown to develop tumors that closely resemble human tumors. However, urothelial carcinoma has not yet been studied in this platform. Methods: We aimed to develop novel Oncopig bladder cancer cell line (BCCL) and investigate whether these urothelial swine cells mimic human bladder cancer cell line (5637 and T24) treatment-responses to cisplatin, doxorubicin, and gemcitabine in vitro. Results: Results demonstrated consistent treatment responses between Oncopig and human cells in most concentrations tested (p>0.05). Overall, Oncopig cells were more predictive of T24 than 5637 cell therapeutic responses. Microarray analysis also demonstrated similar alterations in expression of apoptotic (GADD45B and TP53INP1) and cytoskeleton-related genes (ZMYM6 and RND1) following gemcitabine exposure between 5637 (human) and Oncopig BCCL cells, indicating apoptosis may be triggered through similar signaling pathways. Molecular docking results indicated that swine and humans had similar Dg values between the chemotherapeutics and their target proteins. Discussion: Taken together, these results suggest the Oncopig could be an attractive animal to model urothelial carcinoma due to similarities in in vitro therapeutic responses compared to human cells. Competing Interests: LBS, LJ, CB, and KS work for Sus Clinicals, which provides the Oncopig and other pig-based preclinical testing services to customers. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Segatto, Simões, Bender, Sousa, Oliveira, Paschoal, Pacheco, Lopes, Seixas, Qazi, Thomas, Chaki, Robertson, Newsom, Patel, Rund, Jordan, Bolt, Schachtschneider, Schook and Collares.) |
| References: | Nat Rev Cancer. 2011 Oct 13;11(11):761-74. (PMID: 21993244) J Biol Chem. 2010 Aug 13;285(33):25500-5. (PMID: 20558744) Nat Cell Biol. 2013 Jan;15(1):2-8. (PMID: 23263379) Cell Death Dis. 2019 May 10;10(5):375. (PMID: 31076571) Nature. 2012 Nov 15;491(7424):393-8. (PMID: 23151582) Adv Exp Med Biol. 2013;793:1-19. (PMID: 24104470) Biochem Biophys Res Commun. 2011 Jan 7;404(1):370-5. (PMID: 21145879) Nat Struct Biol. 2003 Jul;10(7):513-9. (PMID: 12808445) PLoS One. 2015 Jul 01;10(7):e0128864. (PMID: 26132737) Int J Mol Sci. 2017 Nov 11;18(11):. (PMID: 29137119) J Vet Intern Med. 1992 May-Jun;6(3):145-53. (PMID: 1619591) Front Mol Biosci. 2021 May 17;8:681044. (PMID: 34079821) Lancet. 2016 Dec 3;388(10061):2796-2810. (PMID: 27345655) Vet Comp Oncol. 2008 Mar;6(1):1-18. (PMID: 19178659) Oncologist. 2006 Apr;11(4):342-57. (PMID: 16614230) J Pharm Bioallied Sci. 2014 Jan;6(1):2-9. (PMID: 24459397) Cell Death Differ. 2005 Apr;12(4):377-83. (PMID: 15706352) Transl Oncol. 2015 Jun;8(3):210-6. (PMID: 26055179) Sci Rep. 2017 Jun 1;7(1):2624. (PMID: 28572589) Toxicol Pathol. 2007 Jun;35(4):495-516. (PMID: 17562483) Nat Rev Cancer. 2003 Dec;3(12):952-9. (PMID: 14737125) Clin Colorectal Cancer. 2012 Jun;11(2):93-100. (PMID: 22154408) Bioarchitecture. 2012 May 1;2(3):75-87. (PMID: 22880146) Nat Rev Mol Cell Biol. 2006 Jan;7(1):54-62. (PMID: 16493413) J Biol Chem. 2003 May 16;278(20):18313-20. (PMID: 12639967) J Exp Clin Cancer Res. 2016 Jan 06;35:2. (PMID: 26733306) Front Genet. 2016 Feb 29;7:28. (PMID: 26973698) Nat Rev Urol. 2015 Apr;12(4):225-35. (PMID: 25800393) Cancer Cell. 2004 Aug;6(2):171-83. (PMID: 15324700) Drug Des Devel Ther. 2017 May 16;11:1517-1533. (PMID: 28553083) World J Urol. 2009 Jun;27(3):295-300. (PMID: 19271220) Cancer Res. 2005 Nov 1;65(21):9824-8. (PMID: 16267004) Anticancer Drugs. 2007 Feb;18(2):179-85. (PMID: 17159604) Bladder Cancer. 2018 Apr 26;4(2):149-159. (PMID: 29732386) Front Oncol. 2017 Aug 23;7:190. (PMID: 28879168) Oncotarget. 2017 Jun 29;8(38):63620-63634. (PMID: 28969016) BMC Biol. 2011 Aug 11;9:54. (PMID: 21834987) Biochem Pharmacol. 2008 Dec 1;76(11):1352-64. (PMID: 18708031) Nat Struct Mol Biol. 2019 Jul;26(7):599-606. (PMID: 31235912) Oncogenesis. 2016 Mar 14;5:e210. (PMID: 26974205) Front Genet. 2013 May 13;4:80. (PMID: 23717325) Int J Biochem Cell Biol. 2007;39(7-8):1476-82. (PMID: 17499002) Front Pharmacol. 2017 Dec 05;8:894. (PMID: 29259556) Nat Rev Cancer. 2015 Jan;15(1):42-54. (PMID: 25533675) Nat Rev Cancer. 2005 Mar;5(3):231-7. (PMID: 15738985) Int J Oncol. 2009 Aug;35(2):401-16. (PMID: 19578756) Sci Rep. 2018 Aug 22;8(1):12548. (PMID: 30135483) Biochem Biophys Res Commun. 2012 Apr 27;421(1):98-104. (PMID: 22490663) Nat Biotechnol. 2013 Feb;31(2):122-4. (PMID: 23392511) Front Oncol. 2019 Feb 25;9:105. (PMID: 30873383) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) BMC Genomics. 2015 Oct 05;16:743. (PMID: 26438392) Exp Ther Med. 2014 Sep;8(3):691-699. (PMID: 25120584) Trends Microbiol. 2012 Jan;20(1):50-7. (PMID: 22153753) |
| فهرسة مساهمة: | Keywords: Oncopig cancer model; bladder cancer; cisplatin; doxorubicin; gemcitabine; in silico; microarray |
| تواريخ الأحداث: | Date Created: 20240312 Latest Revision: 20240313 |
| رمز التحديث: | 20240313 |
| مُعرف محوري في PubMed: | PMC10926022 |
| DOI: | 10.3389/fonc.2024.1323422 |
| PMID: | 38469237 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2024.1323422 |